Case Study: Nitrosamine Risk Assessment for a Proton Pump Inhibitor Seeking ANDA Approval
Introduction A comprehensive Nitrosamine Risk Assessment for a Proton Pump Inhibitor seeking Abbreviated New Drug Application (ANDA) approval requires a […]
Case Study: Nitrosamine Risk Assessment and Testing for a Combination Oral Solid Dosage Form with Multiple APIs
Introduction: Nitrosamine Risk Assessment for Combination Oral Solid Dosage Forms is particularly important when a pharmaceutical product contains two or
Nitrosamine Leachables Testing: From Risk Assessment to Confirmatory LC-MS/MS Analysis
Introduction Nitrosamine Leachables Testing is a comprehensive analytical and regulatory process used to evaluate pharmaceutical packaging and drug delivery systems
Nitrosamine Leachables Testing: From Risk Assessment to Confirmatory LC-MS/MS Analysis Read More »
Nitrosamine Testing for Antidepressants and SSRIs: NDSRI Risk Assessment and CRO Services
Introduction Nitrosamine Testing for Antidepressants and SSRIs is a specialized analytical and regulatory process designed to detect, quantify, and control
Nitrosamine Testing for Antibiotics and Beta-Lactam APIs: Structural Risks and Analytical Approach
Introduction Nitrosamine Testing for Antibiotics and Beta-Lactam APIs is a specialized analytical mandate focused on the detection, identification, and quantification
Nitrosamine Risk in Drug-Drug Combination Products: How Multiple APIs Amplify Formation Risk
Introduction Nitrosamine Risk in Drug-Drug Combination Products has emerged as a significant toxicological challenge because combining multiple active pharmaceutical ingredients
Nitrosamines from Excipients: How Common Pharmaceutical Excipients Contribute to Nitrosamine Formation Risk
Introduction Nitrosamines from Excipients primarily arise when trace levels of nitrite impurities present in inactive formulation components react with susceptible
Nitrosamine Control Strategy Development Services: From Risk Assessment to Regulatory Submission
Introduction Nitrosamine Control Strategy Development Services offer a comprehensive, science-driven framework for identifying, quantifying, and controlling mutagenic N-nitroso impurities throughout
Nitrosamine Testing for Injectable Drug Products: Parenteral Formulation Challenges and Regulatory Requirements
Introduction: Implementation of Nitrosamine Testing for Injectable Drug Products is a critical safety and regulatory requirement because parenteral drug products
When Should You Start Nitrosamine Risk Assessment in Your Drug Development Program?
Introduction A formal nitrosamine risk assessment should begin during the preclinical stage of development, specifically during candidate selection and the
When Should You Start Nitrosamine Risk Assessment in Your Drug Development Program? Read More »